Company intelligence / Profile preview
Remix Therapeutics
Watertown, Massachusetts, United Statesremixtx.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Clinical
01
Overview
Remix Therapeutics has advanced multiple small molecule programs targeting RNA processing into the clinic. The company leverages its proprietary REMaster™ platform to identify and modulate disease-driving RNAs. It recently entered a major collaboration with Roche for discovery and development of small molecule therapeutics modulating RNA processing[3]. Specific clinical results have not been detailed in public sources as of May 2025.
- Therapeutic areas
- Rare Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Roche (collaboration for discovery/development using REMaster™ platform)[3]
Beyond the preview
Go deeper on Remix Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Remix Therapeutics.